Product Name: Tesamorelin (Tesa)
Type: Growth Hormone Pathway Research Peptide

Research Focus:

Tesamorelin is a synthetic 44-amino-acid peptide analog of Growth Hormone-Releasing Hormone (GHRH)[1]. It stimulates endogenous growth hormone release and raises IGF-1 levels, leading to enhanced lipolysis and metabolic benefits[2]. Tesamorelin is FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy and is studied for metabolic disorders and aging research[3][4].

Research Interest:

• Body fat and metabolism signaling studies

• Tissue maintenance and repair signaling models

• Hormone-regulated energy balance research

• Age-related metabolic pathway exploration

Scientific Interest:

• Growth hormone release mechanisms

• Endocrine influence on metabolic processes

• Cellular growth and maintenance signaling
  
  
  

Reconstitution:

• Reconstitute: Add 3.0 mLbacteriostatic water per 20 mg vial → ~6.67 mg/mL concentration.

• Standard daily dose: 2 mg (2000 mcg) once daily subcutaneously (FDA-approved protocol).

• Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U-100 insulin syringe.

• Storage: Lyophilized & Reconstituted: refrigerate at 2–8 °C (35.6–46.4 °F)

Cycle:

Standard FDA-Approved Protocol (3.0 mL = ~6.67 mg/mL)

Frequency: Inject once dailysubcutaneously, preferably in the evening to coincide with nocturnal GH release[5][6]. The 2 mg daily dose is the standard FDA-approved regimen for HIV lipodystrophy[7][8]. A one-week titration at 1 mg may improve tolerability before advancing to the full 2 mg dose.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.

2. Inject slowly down the vial wall; avoid foaming.

3. Gently swirl until dissolved (do not shake).

4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

IMPORTANT NOTICE:

This product is intended strictly for laboratory research. It is not intended to diagnose, treat, cure, or prevent any disease.